Robert W. Baird Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT - Free Report) had its target price reduced by Robert W. Baird from $200.00 to $193.00 in a report issued on Thursday,Benzinga reports. They currently have an outperform rating on the biotechnology company's stock.

Other research analysts have also recently issued reports about the stock. Evercore ISI decreased their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a report on Thursday. Needham & Company LLC reiterated a "buy" rating and set a $205.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday. Royal Bank of Canada reissued an "outperform" rating and set a $182.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Barclays reduced their price target on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. Finally, Cantor Fitzgerald raised Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $152.00 to $167.00 in a research report on Thursday. One analyst has rated the stock with a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $181.33.

Sarepta Therapeutics Price Performance

Shares of SRPT traded down $7.55 during trading hours on Thursday, hitting $120.42. 2,392,656 shares of the company were exchanged, compared to its average volume of 776,954. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The company has a market capitalization of $11.48 billion, a PE ratio of 267.61 and a beta of 0.81. The firm has a fifty day simple moving average of $126.20 and a 200-day simple moving average of $132.77. Sarepta Therapeutics has a one year low of $75.85 and a one year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. Sarepta Therapeutics's revenue was up 38.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.27) earnings per share. As a group, sell-side analysts predict that Sarepta Therapeutics will post 1.48 earnings per share for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO Ian Michael Estepan sold 5,985 shares of the business's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company's stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Andrew Chambers purchased 37,038 shares of the firm's stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares in the company, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 7.70% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. Riggs Asset Managment Co. Inc. increased its position in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 75 shares in the last quarter. CIBC Asset Management Inc increased its holdings in shares of Sarepta Therapeutics by 3.3% in the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company's stock valued at $339,000 after purchasing an additional 86 shares in the last quarter. EP Wealth Advisors LLC raised its position in Sarepta Therapeutics by 2.1% in the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company's stock worth $774,000 after purchasing an additional 103 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in Sarepta Therapeutics by 1.9% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company's stock worth $1,000,000 after buying an additional 120 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its position in Sarepta Therapeutics by 3.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company's stock valued at $557,000 after buying an additional 145 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.